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Background: The Patient‐Oriented Eczema Measure (POEM) is the core
outcome instrument recommended for measuring patient‐reported atopic
eczema symptoms in clinical trials. To ensure that the statistical significance
of clinical trial results is meaningful, trials are often designed by specifying
the target difference in the primary outcome as part of the sample size
calculation. One method used to specify the target difference is a score that
corresponds to a standardized effect size.
Objectives: to assess how the standardized effect size of POEM scores
vary across age, gender, ethnicity and disease severity.
Methods: This study combined data from five UK‐based randomized clinical
trials of eczema treatments in order to assess differences in self‐reported
eczema symptoms (POEM) corresponding to a standardized effect size
(0.5 SD of baseline POEM scores) across age, gender, ethnicity and dis-
ease severity.
Results: POEM scores corresponding to 0.5 SD(baseline) were remarkably
consistent across participants of varying ages, gender, ethnicity and dis-
ease severity from datasets of five UK trials in children (range 2.99–3.45).
Conclusions: This study provides information that can support those
designing clinical trials to determine their sample size and can aid in-
dividuals interpreting trial results. Further exploration of differences in
populations beyond the United Kingdom is needed.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided
the original work is properly cited.
© 2021 The Authors. Skin Health and Disease published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
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1 | INTRODUCTION
The Patient‐Oriented Eczema Measure (POEM) is a 7‐
question patient‐reported measure of atopic eczema
severity assessed over the previous week and scored
0 to 28.1 POEM is recommended for inclusion in all
eczema clinical trials by the Harmonising Outcome
Measures in Eczema (HOME) initiative.2 When
designing clinical trials with POEM as a primary
outcome, the target difference in the primary outcome
needs to be stated as part of the sample size calcula-
tion.3 Cook et al. have identified methods that can be
used to assess whether the target difference specified
is important and/or realistic.3
One approach to specifying a target difference is to
use the minimally important change (MIC), defined as
‘the smallest change in score in the construct to be
measured which patients perceive as important’.4
Anchor‐based methods to calculate the MIC of an in-
strument look how change on the instrument corre-
sponds to change on a different instrument (the
‘anchor’).
Another method commonly used to specify the dif-
ference to be detected in sample size calculations is a
distribution‐based approach based on the standard-
ized effect size.3 The effect size is the change in scores
between baseline and post‐treatment divided by the
standard deviation of baseline scores.5,6 It has been
suggested the difference to be detected in clinical trials,
based on a medium effect size, could be specified as
the score that corresponds to 0.5 SD(baseline). This is the
method that is used within this study. Some have sug-
gested this provides a threshold of detection, which is
conceptually related to minimally detectable change.4
Essentially, this means eczema clinical trials should not
design their studies to detect a target difference smaller
than the score on POEM which corresponds to 0.5
SD(baseline) as it is unlikely to be considered a mean-
ingful difference in POEM scores.
We have explored different anchor‐ and
distribution‐based methods in a previous article.7
Recommendations for interpreting changes in POEM
scores based on three published studies using both
anchor‐ and distribution‐based approaches suggest
the following: ≤2, unlikely to be a change beyond
measurement error; 2.1–2.9, a small change detected
that is likely to be beyond measurement error but may
not be clinically important; 3–3.9, probably a clinically
important change; ≥4, very likely to be a clinically
important change.7–9 However, participant character-
istics could potentially influence what difference would
be important to specify in a sample size calculation,
thus potentially limiting the generalizability of these
recommendations.10 The aim of this study was to
assess how the POEM scores that correspond to the
standardized effect size (0.5 SD) are influenced by
age, gender, ethnicity and disease severity in these
studies.
2 | METHODS
Secondary analysis was conducted on datasets from
five clinical trials including children from the United
Kingdom. Data sets were chosen due to availability, so
may not be inclusive of all eczema trials within the
United Kingdom. As this study made secondary use of
existing trial datasets, further ethics approval was not
required, and this was confirmed by the University of
Nottingham's Faculty of Medicine & Health Sciences
Research Ethics Committee (Ref: 258‐1712). The pro-
tocol was prospectively registered on the CEBD pro-
tocol registration portal: https://www.nottingham.ac.uk/
research/groups/cebd/resources/protocol‐registration.
aspx.
POEM measures patient‐reported frequency of itch,
sleep disturbance, bleeding, weeping/oozing, cracking,
and flaking and dryness/roughness over the past week.
Each item is weighted equally and scored as 0 (no
days), 1 (1–2 days), 2 (3–4 days), 3 (5–6 days) or 4
(every day). Age, gender and ethnicity variables in each
dataset were transformed into a priori defined cate-
gories (Table 1).
WHAT IS ALREADY KNOWN ABOUT THIS
TOPIC?
� Little is known about how participant charac-
teristics might influence the difference that is
important to detect when calculating sample
size requirements for clinical trials.
WHAT DOES THIS STUDY ADD?
� Using the combined dataset across UK clin-
ical trials including children with eczema,
POEM scores corresponding to the stan-
dardized effect size 0.5 SD(baseline) was
remarkably consistent across participants of
varying ages, gender, ethnicity and disease
severity.
� This provides reassurance for those
designing or interpreting the results of
eczema clinical trials that have used POEM
as their primary outcome that the specified
difference can be consistent in a variety of
eczema populations and recruitment settings.
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Baseline POEM scores and patient characteristic
variables from each trial were combined in one dataset
in STATA Version 14. To explore the impact of disease
severity, we calculated the overall mean, standard de-
viation and 0.5 SD of baseline POEM for each trial
separately (as each trial recruited participants with
different eczema severities). We also combined indi-
vidual participant data to calculate the mean, standard
deviation and 0.5 SD for overall sample and for each
age, ethnicity and gender category.
3 | RESULTS
Data from 1426 participants across five UK trials were
combined. All five trials included children in the cate-
gories 0–2 years and 3–7 years. The CLOTHES, SWET
and BATHE trials included some children in the
8–17 years category, however this was the least
frequent age in all three trials. Gender was roughly
equally distributed within all trials. Most participants
across all trials were white (79%) (Table 1).
POEM scores corresponding to the standardized
effect size from each of the five trials of children in the
United Kingdom ranged from 2.68 to 2.95 (Table 2).
When the individual participant data from these trials
were combined and categorized according to age,
ethnicity and gender, the POEM scores corresponding
to the standardized effect size ranged from 2.99 to
3.45.
4 | DISCUSSION
The POEM score corresponding to the standardized
effect size was remarkably consistent across partici-
pants of varying ages, gender, ethnicity and disease
severity. Previous studies that have used both anchor‐
and distribution‐based methods to estimate the MIC
found that anchor‐based methods suggested a larger
difference would need to be detected than the stan-
dardized effect size approach.7,8 Our findings are
consistent with previous findings that a score less than
2 is unlikely to be a change beyond measurement
error and support a stance that the specification of a
target difference should be no lower than 2 when
designing trials, as all 0.5 SD scores were above 2
points across the different participant characteristics.
Previous research also suggests that changes in
POEM scores less than 3 are unlikely to be clinically
TABLE 1 Summary of datasets used





















































Primary care Primary care Primary care
Location of
recruitment
UK UK UK UK UK
N 300 336 482 196 112
Age N (%)
0–2 125 (42) 131 (39) 191 (40) 170 (87) 65 (58)
3–7 114 (38) 136 (40) 221 (46) 26 (13) 47 (42)
8–17 61 (20) 69 (21) 70 (14) 0 0
Ethnicity N (%)
Not white 63 (21) 74 (22) 75 (16) 29 (15) 19 (17)
White 237 (79) 260 (77) 397 (82) 155 (79) 91 (81)
Missing data 0 2 (1) 10 (2) 12 (6) 2 (2)
Female N (%) 126 (42) 143 (43) 244 (51) 85 (43) 51 (46)
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relevant. However, researchers and clinicians need to
be cautious about relying on fixed values to interpret
the importance of a change on the POEM and
continue to consider the context within which they are
using the POEM. A small improvement in many in-
dividuals could result in a large reduction in burden at
a societal level.
It has been cautioned that the SD used to calculate
the standardized effect size needs to reflect the SD for
the population of interest for the results to be used
appropriately.3,16 This study should give reassurance
that the participant characteristics of age, ethnicity,
sex and disease severity do not appear to influence
the SD.
Given that datasets were chosen based on avail-
ability, they may not be fully representative of eczema
trials including children within the United Kingdom.
There are also limits on how confidently the results from
this study can be applied to wider populations beyond
children in the United Kingdom, such as those nations
with larger documented ethnic and economic disparities
in health outcomes. Further exploration in different
populations is warranted. We can compare our results
with the 0.5 SD we have calculated for the trial of
methotrexate versus azathioprine for severe atopic
dermatitis (MAcAD) (Dutch trial register: NTR1916).17
MAcAD is a Dutch trial that included 43 adults with
severe eczema. Twenty (46.5%) female and 38
(88.4%) reported white ethnicity. 0.5 SD from this
sample was 2.32. This is slightly lower than that of the
UK trials in children, but still relatively consistent with
the results.17
There are characteristics that vary amongst in-
dividuals that may influence the target difference that
should be specified in a clinical trial. Some examples
include body surface area of involved skin, pheno-
type, and whether the POEM was completed by
parent or the child themselves. We were limited to
exploring variables that were collected in the trial
datasets.
TABLE 2 UK trials including children: The POEM scores corresponding to 0.5 SD(baseline) by trial, age, gender, ethnicity and baseline

















300 2.68 16.95 (5.36) 4 28 13, 20
Moderate—severe
eczema (SWET)
336 2.95 16.87 (5.90) 0 28 12.5, 22
All severities of
eczema (BATHE)
428 2.88 9.77 (5.76) 0 28 6, 13
All severities of
eczema (COMET)
196 2.94 8.80 (5.87) 0 28 4, 12
Clinically infected
eczema (CREAM)
112 2.69 14.99 (5.38) 6 28 11, 18.5
Age
0–2 682 3.25 12.46 (6.50) 0 28 8, 17
3–7 544 3.40 13.41 (6.80) 0 28 8, 18
8–17 200 3.44 15.39 (6.87) 0 28 9.5, 20.5
Ethnicity
White 1140 3.45 14.36 (6.89) 0 28 8, 18
Not white 260 3.34 13.05 (6.68) 0 28 9, 20
Gender
Male 777 3.43 13.55 (6.85) 0 28 8, 19
Female 649 3.30 12.85 (6.59) 0 28 8, 17
Note: Age, ethnicity and gender are the combined data from all five trials.
aQ1 = lower quartile, Q3 = upper quartile.
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The POEM score corresponding to the standard-
ized effect size does not appear to be influenced by
age, gender, ethnicity or disease severity of the popu-
lation, which provides useful information for those
designing or interpreting trials with POEM as the pri-
mary outcome.
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